Clinical trialPhase 1 / Phase 2Terminated
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
- Outcome
- Stopped early. Results posted; no analysis attachedStudy terminated due to safety issues. (Toxicity)
- Phase
- Phase 1 / Phase 2
- Status
- Terminated
- Study type
- Interventional
- Start
- 18 May 2016
- Ended
- 13 February 2019
- Enrollment
- 137 participants
- Sites
- 18
- Primary outcomes
- Number of Participants With Treatment Emergent Adverse Events (TEAE's).
- Sponsor type
- Industry
- Results posted
- 28 April 2022
- Last update
- 21 October 2025
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Results
- Primary endpoint
- Results posted; no analysis attachedAs posted on ClinicalTrials.gov ↗, registry record of 21 October 2025
- Primary outcome
- Number of Participants With Treatment Emergent Adverse Events (TEAE's).Part1/Treatment Group A : 8mg QD INCB057643: 4, n = 4Part1/Treatment Group A : 12mg QD INCB057643: 5, n = 5Part1/Treatment Group A : 16mg QD INCB057643: 8, n = 8Part1/Treatment Group B : 8mg QD INCB057643: 7, n = 7Part1/Treatment Group B : 12mg QD INCB057643: 5, n = 5Part1/Treatment Group C : 8mg QD INCB057643: 1, n = 1Part2/Treatment Group A : 12 mg INCB057643 Expansion Cohort: 86, n = 86Part2/Treatment Group B : 12 mg INCB057643 Expansion Cohort: 5, n = 5Values: ParticipantsTime frame: From screening through at least 30 days after end of treatment, up to approximately 24 monthsNo analysis posted for this outcome (outcome 1)
- Participants
- Part1/Treatment Group A : 8mg QD INCB057643: 4 started, 0 completedPart1/Treatment Group A : 12mg QD INCB057643: 5 started, 0 completedPart1/Treatment Group A : 16mg QD INCB057643: 8 started, 0 completedPart1/Treatment Group B : 8mg QD INCB057643: 7 started, 0 completedPart1/Treatment Group B : 12mg QD INCB057643: 5 started, 0 completedPart1/Treatment Group C : 8mg QD INCB057643: 1 started, 0 completedPart2/Treatment Group A : 12 mg INCB057643 Expansion Cohort: 86 started, 0 completedPart2/Treatment Group B : 12 mg INCB057643 Expansion Cohort: 5 started, 0 completedPart3/Treatment Group A : 8 mg INCB057643 + Gemcitabine 1000mg: 1 started, 0 completedPart3/Treatment Group B : 8 mg INCB057643 + Paclitaxel 80mg: 2 started, 0 completedPart3/Treatment Group C : 8 mg INCB057643 + Rucaparib 600mg: 4 started, 0 completedPart3/Treatment Group D : 8 mg INCB057643 + Abir +Predni: 3 started, 0 completedPart3/Treatment Group E : 8 mg INCB057643 + Ruxolitinib 20mg: 1 started, 0 completedPart3/Treatment Group F : 8 mg INCB057643 + Azacitidine 75mg: 2 started, 0 completedEnrolled But Not Dosed: 3 started, 0 completed
- Serious adverse events
- Part1/Treatment Group A : 8mg QD INCB057643: 2 of 4Part1/Treatment Group A : 12mg QD INCB057643: 1 of 5Part1/Treatment Group A : 16mg QD INCB057643: 4 of 8Part1/Treatment Group B : 8mg QD INCB057643: 5 of 7Part1/Treatment Group B : 12mg QD INCB057643: 4 of 5Part1/Treatment Group C : 8mg QD INCB057643: 1 of 1Part2/Treatment Group A : 12 mg INCB057643 Expansion Cohort: 32 of 86Part2/Treatment Group B : 12 mg INCB057643 Expansion Cohort: 4 of 5Part3/Treatment Group A : 8 mg INCB057643 + Gemcitabine 1000mg: 0 of 1Part3/Treatment Group B : 8 mg INCB057643 + Paclitaxel 80mg: 0 of 2Part3/Treatment Group C : 8 mg INCB057643 + Rucaparib 600mg: 0 of 4Part3/Treatment Group D : 8 mg INCB057643 + Abir +Predni: 1 of 3Part3/Treatment Group E : 8 mg INCB057643 + Ruxolitinib 20mg: 1 of 1Part3/Treatment Group F : 8 mg INCB057643 + Azacitidine 75mg: 0 of 2Participants with at least one serious adverse event, of those at risk, as posted
9 secondary outcomes, the first 8 shown
- Percent Inhibition of Total Cellular Myc Protein Concentrations Before and After Administ…
- C1D1: 8mg QD INCB057643 24 (199.5), n=11; 12mg QD INCB057643 28 (200.1), n=51; 16mg QD INCB057643 54 (236.3), n=7 [mean %Inhibition of Total c-Myc, Standard Error] (first of 2 rows)
- ORR · Objective Response Rate (ORR) With INCB057643 in Solid Tumors
- Solid Tumors: Part1/Treatment Group A : 8mg QD INCB05… 0, n=3; Part1/Treatment Group A : 12mg QD INCB0… 0, n=4; Part1/Treatment Group A : 16mg QD INCB0… 0, n=6; Part2/Treatment Group A : 12 mg INCB057… 0, n=63; Part3/Treatment Group A : 8 mg INCB0576… 0, n=1; Part3/Treatment Group B : 8 mg INCB0576… 1, n=2; Part3/Treatment Group C : 8 mg INCB0576… 0, n=4; Part3/Treatment Group D : 8 mg INCB0576… 0, n=3 [Participants] (first of 7 rows)
- Cmax: Maximum Observed Plasma Concentration of INCB057643.
- C1D1: 8mg QD INCB057643 201 (83.6), n=12; 12mg QD INCB057643 266 (94.7), n=99; 16mg QD INCB057643 343 (93.2), n=7 [mean nM, Standard Deviation] (first of 2 rows)
- Tmax: Time to Maximum Plasma Concentration of INCB057643
- C1D1: 8mg QD INCB057643 2.00 (1.00 to 24.00), n=12; 12mg QD INCB057643 2 (0.50 to 8.00), n=99; 16mg QD INCB057643 2.00 (2.00 to 4.00), n=7 [median hours, Full Range] (first of 2 rows)
- AUC0-t: Area Under the Single-dose Plasma Concentration-time Curve of INCB057643
- 8mg QD INCB057643 2090 (50.1), n=12; 12mg QD INCB057643 2550 (39.5), n=99; 16mg QD INCB057643 3210 (34.3), n=7 [mean h*nM, Standard Deviation]
- AUC0-24: Area Under the Steady-state Plasma Concentration-time Curve of INCB057643 Admini…
- 8mg QD INCB057643 1940 (45.1), n=10; 12mg QD INCB057643 2740 (43.2), n=89; 16mg QD INCB057643 3610 (71.9), n=7 [mean h*nM, Standard Deviation]
- Part 2 - Cmax: Maximum Observed Plasma Concentration of INCB057643.
- 12mg QD INCB057643 220 (32.0), n=11 [mean nM, Standard Deviation]
- Part 2-Tmax: Time to Maximum Plasma Concentration of INCB057643
- 12mg QD INCB057643 6.00 (4.00 to 8.00), n=11 [median hours, Full Range]
Every value is copied from the trial’s results record at ClinicalTrials.gov. “Statistically significant” describes the posted test only: it does not say which group did better, and nothing here is read from a paper.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
The purpose of the Study is to select a dose and assess the safety and tolerability of INCB057643 as a monotherapy (Part 1 and Part 2) and in combination with standard-of-care (SOC) agents (Part 3 and Part 4) for subjects with advanced malignancies. Part 1 will determine the maximum tolerated dose of INCB057643 and/or a tolerated dose that demonstrates sufficient pharmacologic activity. Part 2 will further evaluate the safety, preliminary efficacy, PK, and PD of the dose(s) selected in Part 1 in select tumor types including solid tumors, lymphomas and other hematologic malignancies. Part 3 will determine the tolerated dose of INCB057643 in combination with select SOC agents; and assess the safety and tolerability of the combination therapy in select advanced solid tumors and hematologic malignancies. Part 4 will further evaluate the safety, preliminary efficacy, PK, and PD of the selected dose combination from Part 3 in 4 specific advanced solid tumor and hematologic malignancies.
Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)
Number of Participants With Treatment Emergent Adverse Events (TEAE's). [From screening through at least 30 days after end of treatment, up to approximately 24 months]. Number, Participants. Part1/Treatment Group A : 8mg QD INCB057643 (n=4): 4; Part1/Treatment Group A : 12mg QD INCB057643 (n=5): 5; Part1/Treatment Group A : 16mg QD INCB057643 (n=8): 8; Part1/Treatment Group B : 8mg QD INCB057643 (n=7): 7; Part1/Treatment Group B : 12mg QD INCB057643 (n=5): 5; Part1/Treatment Group C : 8mg QD INCB057643 (n=1): 1; Part2/Treatment Group A : 12 mg INCB057643 Expansion Cohort (n=86): 86; Part2/Treatment Group B : 12 mg INCB057643 Expansion Cohort (n=5): 5; Part3/Treatment Group A : 8 mg INCB057643 + Gemcitabine 1000mg (n=1): 1; Part3/Treatment Group B : 8 mg INCB057643 + Paclitaxel 80mg (n=2): 2; Part3/Treatment Group C : 8 mg INCB057643 + Rucaparib 600mg (n=4): 4; Part3/Treatment Group D : 8 mg INCB057643 + Abir +Predni (n=3): 3; Part3/Treatment Group E : 8 mg INCB057643 + Ruxolitinib 20mg (n=1): 1; Part3/Treatment Group F : 8 mg INCB057643 + Azacitidine 75mg (n=2): 2.
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Percent Inhibition of Total Cellular Myc Protein Concentrations Before and After Administration of INCB057643 When Administered as Monotherapy in an Ex-vivo Assay [PD in plasma at pre-dose and 0.5, 1, 2, 4, 6 and 8 hours postdose, for C1D1 and C1D8, and 24hrs post dose for C1D1]. Mean, %Inhibition of Total c-Myc (Standard Error). C1D1: 8mg QD INCB057643 (n=11): 24 (199.5); 12mg QD INCB057643 (n=51): 28 (200.1); 16mg QD INCB057643 (n=7): 54 (236.3). C1D8: 8mg QD INCB057643 (n=11): 30 (42.59); 12mg QD INCB057643 (n=51): 43.4 (52.7); 16mg QD INCB057643 (n=7): 65 (55.21).
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Objective Response Rate (ORR) With INCB057643 in Solid Tumors [Efficacy measures from screening through end of treatment and follow-up (every 9 weeks), up to approximately 24 months]. Number, Participants. Solid Tumors: Part1/Treatment Group A : 8mg QD INCB057643 (n=4): 0; Part1/Treatment Group A : 12mg QD INCB057643 (n=5): 0; Part1/Treatment Group A : 16mg QD INCB057643 (n=8): 0; Part2/Treatment Group A : 12 mg INCB057643 Expansion Cohort (n=86): 0; Part3/Treatment Group A : 8 mg INCB057643 + Gemcitabine 1000mg (n=1): 0; Part3/Treatment Group B : 8 mg INCB057643 + Paclitaxel 80mg (n=2): 1; Part3/Treatment Group C : 8 mg INCB057643 + Rucaparib 600mg (n=4): 0; Part3/Treatment Group D : 8 mg INCB057643 + Abir +Predni (n=3): 0. Lymphoma: Part1/Treatment Group A : 8mg QD INCB057643 (n=4): 1; Part1/Treatment Group A : 12mg QD INCB057643 (n=5): 0; Part1/Treatment Group A : 16mg QD INCB057643 (n=8): 1; Part2/Treatment Group A : 12 mg INCB057643 Expansion Cohort (n=86): 2. AML: Part1/Treatment Group B : 8mg QD INCB057643 (n=7): 0; Part1/Treatment Group B : 12mg QD INCB057643 (n=5): 0; Part2/Treatment Group B : 12 mg INCB057643 Expansion Cohort (n=5): 1; Part3/Treatment Group F : 8 mg INCB057643 + Azacitidine 75mg (n=2): 0. Glioblastoma: Part2/Treatment Group A : 12 mg INCB057643 Expansion Cohort (n=86): 0. Myelodysplastic Syndrome: Part1/Treatment Group B : 8mg QD INCB057643 (n=7): 0; Part1/Treatment Group B : 12mg QD INCB057643 (n=5): 0; Part2/Treatment Group B : 12 mg INCB057643 Expansion Cohort (n=5): 0. Myelofibrosis: Part1/Treatment Group B : 8mg QD INCB057643 (n=7): 0; Part2/Treatment Group B : 12 mg INCB057643 Expansion Cohort (n=5): 0; Part3/Treatment Group E : 8 mg INCB057643 + Ruxolitinib 20mg (n=1): 0. Multiple Myeloma: Part1/Treatment Group C : 8mg QD INCB057643 (n=1): 0.
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Cmax: Maximum Observed Plasma Concentration of INCB057643. [Predose, 0.5, 1, 2, 4, 6, 8 hours on C1D1 and C1D8]. Mean, nM (Standard Deviation). C1D1: 8mg QD INCB057643 (n=12): 201 (83.6); 12mg QD INCB057643 (n=99): 266 (94.7); 16mg QD INCB057643 (n=7): 343 (93.2). C1D8: 8mg QD INCB057643 (n=12): 210 (93.2); 12mg QD INCB057643 (n=99): 293 (113); 16mg QD INCB057643 (n=7): 340 (165).
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Tmax: Time to Maximum Plasma Concentration of INCB057643 [Predose, 0.5, 1, 2, 4, 6, 8 hours on C1D1 and C1D8]. Median, hours (Full Range). C1D1: 8mg QD INCB057643 (n=12): 2.00 (1.00 to 24.00); 12mg QD INCB057643 (n=99): 2 (0.50 to 8.00); 16mg QD INCB057643 (n=7): 2.00 (2.00 to 4.00). C1D8: 8mg QD INCB057643 (n=12): 1.00 (1.00 to 4.00); 12mg QD INCB057643 (n=99): 2 (0.50 to 8.00); 16mg QD INCB057643 (n=7): 2.00 (2.00 to 4.00).
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
AUC0-t: Area Under the Single-dose Plasma Concentration-time Curve of INCB057643 [Predose, 0.5, 1, 2, 4, 6, 8 hours on C1D1]. Mean, h*nM (Standard Deviation). 8mg QD INCB057643 (n=12): 2090 (50.1); 12mg QD INCB057643 (n=99): 2550 (39.5); 16mg QD INCB057643 (n=7): 3210 (34.3).
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
AUC0-24: Area Under the Steady-state Plasma Concentration-time Curve of INCB057643 Administered as Monotherapy [Predose, 0.5, 1, 2, 4, 6, 8 hours on C1D8]. Mean, h*nM (Standard Deviation). 8mg QD INCB057643 (n=10): 1940 (45.1); 12mg QD INCB057643 (n=89): 2740 (43.2); 16mg QD INCB057643 (n=7): 3610 (71.9).
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Part 2 - Cmax: Maximum Observed Plasma Concentration of INCB057643. [C2D1]. Mean, nM (Standard Deviation). 12mg QD INCB057643 (n=11): 220 (32.0).
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Part 2-Tmax: Time to Maximum Plasma Concentration of INCB057643 [C2D1]. Median, hours (Full Range). 12mg QD INCB057643 (n=11): 6.00 (4.00 to 8.00).
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
AUC0-24: Area Under the Steady-state Plasma Concentration-time Curve of INCB057643 Administered as Monotherapy [C2D1]. Mean, h*nM (Standard Deviation). 12mg QD INCB057643 (n=11): 2980 (31.5).